TY - JOUR
T1 - Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel
T2 - Crystallographic and Biological Characterization of a Model Chemotype
AU - Olaoye, Olasunkanmi O.
AU - Watson, Paris R.
AU - Nawar, Nabanita
AU - Geletu, Mulu
AU - Sedighi, Abootaleb
AU - Bukhari, Shazreh
AU - Raouf, Yasir S.
AU - Manaswiyoungkul, Pimyupa
AU - Erdogan, Fettah
AU - Abdeldayem, Ayah
AU - Cabral, Aaron D.
AU - Hassan, Muhammad Murtaza
AU - Toutah, Krimo
AU - Shouksmith, Andrew E.
AU - Gawel, Justyna M.
AU - Israelian, Johan
AU - Radu, Tudor B.
AU - Kachhiyapatel, Niyati
AU - De Araujo, Elvin D.
AU - Christianson, David W.
AU - Gunning, Patrick T.
N1 - Publisher Copyright:
©
PY - 2021/3/11
Y1 - 2021/3/11
N2 - Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious in both preclinical and clinical studies. While selective HDAC6 targeting has been pursued as an alternative to pan-HDAC drugs, identifying truly selective molecular templates has not been trivial. Herein, we report a structure-activity relationship study yielding TO-317, which potently binds HDAC6 catalytic domain 2 (Ki = 0.7 nM) and inhibits the enzyme function (IC50 = 2 nM). TO-317 exhibits 158-fold selectivity for HDAC6 over other HDAC isozymes by binding the catalytic Zn2+ and, uniquely, making a never seen before direct hydrogen bond with the Zn2+ coordinating residue, His614. This novel structural motif targeting the second-sphere His614 interaction, observed in a 1.84 Å resolution crystal structure with drHDAC6 from zebrafish, can provide new pharmacophores for identifying enthalpically driven, high-affinity, HDAC6-selective inhibitors.
AB - Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious in both preclinical and clinical studies. While selective HDAC6 targeting has been pursued as an alternative to pan-HDAC drugs, identifying truly selective molecular templates has not been trivial. Herein, we report a structure-activity relationship study yielding TO-317, which potently binds HDAC6 catalytic domain 2 (Ki = 0.7 nM) and inhibits the enzyme function (IC50 = 2 nM). TO-317 exhibits 158-fold selectivity for HDAC6 over other HDAC isozymes by binding the catalytic Zn2+ and, uniquely, making a never seen before direct hydrogen bond with the Zn2+ coordinating residue, His614. This novel structural motif targeting the second-sphere His614 interaction, observed in a 1.84 Å resolution crystal structure with drHDAC6 from zebrafish, can provide new pharmacophores for identifying enthalpically driven, high-affinity, HDAC6-selective inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85101593613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101593613&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.0c01922
DO - 10.1021/acs.jmedchem.0c01922
M3 - Article
C2 - 33576627
AN - SCOPUS:85101593613
SN - 0022-2623
VL - 64
SP - 2691
EP - 2704
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 5
ER -